Prevalence of Sarcopenia in Patients Admitted to ICU and Its Progression During Hospitalization.

This is a prospective, observational study at the ICU of Hospital Mútua de Terrassa, running from May to December 2025. The primary goal is to determine the prevalence of sarcopenia in adult patients requiring more than 48 hours of mechanical ventilation. Sarcopenia is assessed using the SARC-F score, impedanciometry, and quadriceps ultrasound. Secondary aims include tracking the development of ICU-Acquired Weakness (ICU-AW) using the MRC score. All data is collected anonymously after obtaining informed consent.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Sarcopenia Atrophy Bio-Impedance Measurements Body Composition Measurement Critical Illness Disease Attributes Intensive Care (ICU) Myopathy Muscular Atrophy Muscular Diseases Musculoskeletal Diseases Nervous System Diseases Neurologic Manifestations Neuromuscular Diseases Neuromuscular Manifestations Pathologic Processes Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Signs and Symptoms Ultrasound Evaluation

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hospital Universitari Mútua Terrassa

Terrassa, Barcelona, 08012, Spain

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Older than 18 years old.
Expected duration of mechanical ventilation (MV) exceeding 48 hours.

Exclusion criteria

Refusal to participate.
Mechanical ventilation not exceeding 48 hours.
Do-not-resuscitate (DNR) orders or limitations of therapeutic effort upon admission.

Treatment and study plan

Primary outcomes

Prevalence of sarcopenia at the time of ICU admission.

Time frame: Baseline at admission to ICU

Describe the prevalence of sarcopenia at the time of ICU admission in patients with an expected duration of mechanical ventilation (MV) exceeding 48 hours.

Secondary outcomes

Detecting patients who develop ICU-Acquired Weakness (ICU-AW) and/or prolonged mechanical ventilation weaning

Time frame: From ICU admission to 30 days follow-up

Detecting patients who develop ICU-Acquired Weakness (ICU-AW) and/or prolonged mechanical ventilation weaning, defined as failure of definitive disconnection from mechanical ventilation
Detecting the appearance of other complications

Time frame: From admission to 30 days follow up

Detecting the appearance of other complications during admission such as: the appearance of refeeding syndrome or increased prevalence of insulin resistance.

Sponsors and collaborators

Lead sponsor

Hospital Mutua de Terrassa

Other

Registry information

Acronym: SARC-ICU

Important dates

Study start: 2025
Primary completion: 2025
Study completion: 2026
First posted: Dec 24, 2025
Registry last updated: Dec 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting